scholarly journals The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de‐escalate treatment regimens in p16‐positive oropharyngeal cancer patients?

2017 ◽  
Vol 141 (7) ◽  
pp. 1490-1491 ◽  
Author(s):  
Paolo Boscolo‐Rizzo ◽  
Andreas Dietz
Keyword(s):  
Head And Neck ◽  
Cancer Patients ◽  
Oropharyngeal Cancer ◽  
Head And Neck Cancers ◽  
Treatment Regimens ◽  
Eighth Edition

scholarly journals Is AJCC/UICC Staging Still Appropriate for Head and Neck Cancers in Developing Countries?

OTO Open ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 2473974X2093831
Author(s):  
Johannes J. Fagan ◽  
Julie Wetter ◽  
Jeffrey Otiti ◽  
Joyce Aswani ◽  
Anna Konney ◽  
...  
Keyword(s):  
Developing Countries ◽  
Head And Neck ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Oropharyngeal Cancer ◽  
Head And Neck Cancers ◽  
Anatomical Location ◽  
African Countries ◽  
International Union ◽  
Do So

By 2030, 70% of cancers will occur in developing countries. Head and neck cancers are primarily a developing world disease. While anatomical location and the extent of cancers are central to defining prognosis and staging, the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) have incorporated nonanatomic factors that correlate with prognosis into staging (eg, p16 status of oropharyngeal cancers). However, 16 of 17 head and neck surgeons from 13 African countries cannot routinely test for p16 status and hence can no longer apply AJCC/UICC staging to oropharyngeal cancer. While the AJCC/UICC should continue to refine staging that best reflects treatment outcomes and prognosis by incorporating new nonanatomical factors, they should also retain and refine anatomically based staging to serve the needs of clinicians and their patients in resource-constrained settings. Not to do so would diminish their global relevance and in so doing also disadvantage most of the world’s cancer patients.

In silico modeling of cellular probabilistic nanoparticle radiosensitization in head and neck cancers

Nanomedicine ◽  
2020 ◽  
Vol 15 (29) ◽  
pp. 2837-2850
Author(s):  
Myxuan Huynh ◽  
Ivan Kempson ◽  
Eva Bezak ◽  
Wendy Phillips
Keyword(s):  
Head And Neck ◽  
Patient Outcomes ◽  
Head And Neck Cancers ◽  
New Approach ◽  
Treatment Regimens ◽  
Therapeutic Benefits ◽  
In Silico Modeling ◽  
The Individual ◽  
Dose Deposition ◽  
Therapy Treatment

Background: The use of gold nanoparticles (AuNPs) as radiosensitizers may offer a new approach in the treatment of head and neck cancers; minimizing treatment-associated toxicities and improving patient outcomes. AuNPs promote localized dose deposition; permitting improved local control and/or dose reduction. Aim: This work aimed to address the theoretical optimization of radiation doses, fractionation and nanoparticle injection schedules to maximize therapeutic benefits. Materials & methods: Probabilistic nanoparticle sensitization factors were incorporated into the individual cell-based HYP-RT computer model of tumor growth and radiotherapy. Results: Total dose outcomes across all radiation therapy treatment regimens were found to be significantly reduced with the presence of AuNPs, with bi-weekly injections showing the most decrease. Conclusion: Outcomes suggest the need for regular AuNP administration to permit effective radiosensitization.

scholarly journals Filipino head and neck cancer patients and their quality of life

2020 ◽  
Vol 6 (3) ◽  
pp. 439
Author(s):  
Frederic Ivan L. Ting ◽  
Aylmer Rex B. Hernandez ◽  
Reno Eufemon P. Cereno ◽  
Irisyl B. Orolfo-Real ◽  
Corazon A. Ngelangel
Keyword(s):  
Quality Of Life ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
The Philippines ◽  
Head And Neck Cancers ◽  
The Social ◽  
The University

<p class="abstract"><strong><span lang="EN-US">Background: </span></strong>In the management of head and neck cancer (HNC), assessment of quality of life (QoL) is imperative because of the potentially debilitating effect of treatment toxicities. Currently, there are no published data assessing the QoL in Filipino HNC patients, thus this study.</p><p class="abstract"><strong><span lang="EN-US">Methods: </span></strong>This cross-sectional study utilized the University of the Philippines - Department of Health Quality of Life scale. Patients with head and neck cancers at the University of the Philippines - Philippine General Hospital from February to September 2019 were invited to participate.  </p><p class="abstract"><strong><span lang="EN-US">Results: </span></strong>A total of 418 patients were included in the study with a mean age of 42 years old (range 18 to 73 years old). In general, Filipino head and neck cancer patients had moderate QoL (mean score of 4.59±0.79). All of the QoL domains (physical, emotional, cognitive, and related functions) had a score of 3-5 (moderate), except for the social status domain which had a mean score of 5.51±0.83 (high). Among socio-demographic factors, patients who are employed and with additional funding sources on top of their income have better global QoL (p&lt;0.01). Clinically, patients with higher stages of disease, fungating tumors, post-laryngectomy, have a feeding tube, with a tracheostomy, and had chemotherapy have lower global QoL (p&lt;0.01).</p><p class="abstract"><strong><span lang="EN-US">Conclusions: </span></strong>Filipino patients with head and neck cancers have an overall moderate quality of life, with high scores in the social domain. Patients with higher tumor burdens and have been exposed to chemotherapy have lower QoL scores, while patients with financial stability and aid have better QoL scores.</p><p class="abstract"><span lang="EN-US"> </span></p>

scholarly journals Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial

2018 ◽  
Vol 29 ◽  
pp. viii378-viii379
Author(s):  
A. Houessinon ◽  
L. Verlingue ◽  
A. Hollebecque ◽  
C. Even ◽  
L. Lacroix ◽  
...  
Keyword(s):  
Head And Neck ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Head And Neck Cancers ◽  
Molecular Screening ◽  
Advanced Cancer Patients

Human papillomavirus (HPV)-related oropharyngeal cancer cofactors: Viral co-infections, second cancers, and survival trends—A single Veterans Administration (VA) institution.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17531-e17531
Author(s):  
George Anthony Dawson ◽  
Yue Hua Zhang ◽  
Angela Laurio ◽  
Patricia Smith ◽  
Michael Dellatto ◽  
...  
Keyword(s):  
Head And Neck ◽  
Survival Data ◽  
Oropharyngeal Cancer ◽  
Statistical Significance ◽  
Small Sample ◽  
Head And Neck Cancers ◽  
Field Cancerization ◽  
Head Neck Cancer ◽  
Second Cancers ◽  
Hpv Status

e17531 Background: Oropharyngeal cancers related to HPV are increasing in number. Common factors associated with HPV related head and neck cancers include ethnicity, young age, and low usage of alcohol and tobacco. All are typical of HPV+ related Oropharyngeal cancer in non-VA populations. Methods: This IRB approved chart review of 73 documented patients with Oropharyngeal cancers from co-HPV infections from 01/01/2011 - 12/31/2016. In this version of report we discuss second cancers, trends and other co-factors. Results: Overall trend was notable for a reversal (more HPV+ / less HPV- ) cases. All cancers were squamous cell variety. 2011 /2012 /2013/ 2014/2015/2016 HPV +: 4 / 4 / 0 / 6 / 11 / 7. HPV -: 6 / 8 / 4 / 8 / 6 / 5. Clinical stage: Evident adenopathy - (N2 to N3) was noted in 51/73(70%) cases: HPV+ 30/36 (83%) / HPV- 21/37(57%). As noted, there are ~40 co-factor events in each group with no clear association with HPV + or – status numbers of cases were too small for meaningful analysis. Second Cancers HPV+: PROSTATE 7 / BLADDER 2 / TESTICULAR 1 / RENAL 1 / LUNG 1 / SKIN 4. HPV- : FOM 2 / LARYNX 2 / TONSILLAR 1 / PAROTID 1 / BLADDER 1 / SKIN 5 / PROSTATE 1 / LUNG 1. Survival data results: There was evidence in our data that survival was prolonged in patients who are HPV negative, but this sample was too small to show statistical significance. Further, it appears white race improves the odds of survival p-value 0.073, however, not statistically significant, due to the small sample. Conclusions: As in the non-VA community, our data noted an increase in HPV+ oropharyngeal cancers treated at the Bronx VA during review period. Further, our HPV+ group had predominant advanced adenopathy, and whites had longer survival regardless of HPV status. Second cancers in HPV- group followed field cancerization effects in regards number new or old head / neck cancer events. Interestingly, with almost equal tobacco / alcohol use in both groups, no 2nd head and neck cancers in the HPV+ group were discovered. Potential immuno-protection for HPV+ 2nd h and N cancers.[Table: see text]

Radiotherapy quadrant doses in oropharyngeal cancer treated with intensity modulated radiotherapy

2020 ◽  
Vol 11 (4) ◽  
pp. 166-172 ◽  
Author(s):  
Vinod Patel ◽  
Laia Humbert-Vidan ◽  
Christopher Thomas ◽  
Isabel Sassoon ◽  
Mark McGurk ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Oropharyngeal Cancer ◽  
Dental Treatment ◽  
Treatment Plan ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated ◽  
Mandatory Requirement ◽  
Head And Neck Radiotherapy

Dental assessment prior to head and neck radiotherapy (RT) is a mandatory requirement. Treatment recommendations are based on perceived doses to the jaw; however, these are poorly understood. In the pre-RT dental assessment phase, oropharyngeal cancer patients present with more teeth than other head and neck cancer patients. Hence, prior knowledge of likely RT doses specific to the dentition would allow the dental oncologist to provide a patient centred dental treatment plan. Identifying dental regions at risk of osteoradionecrosis from post-radiotherapy events provides invaluable information.

Evaluation of Efficacy of an Herbal Compound on Dry Mouth in Patients With Head and Neck Cancers

2015 ◽  
Vol 21 (1) ◽  
pp. 30-33 ◽  
Author(s):  
Ahmad Ameri ◽  
Ghazaleh Heydarirad ◽  
Hossein Rezaeizadeh ◽  
Rasool Choopani ◽  
Ali Ghobadi ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Visual Analog Scale ◽  
Neck Cancer ◽  
Head And Neck Cancers ◽  
Dry Mouth ◽  
Analog Scale ◽  
Significant Difference ◽  
Herbal Compound

Dry mouth is a common complication of radiotherapy for head and neck cancers. This study compared the efficacy of an herbal compound containing Malva sylvestris and Alcea digitata (Boiss) with artificial saliva (Hypozalix) for improving the symptoms of dry mouth in head and neck cancer patients. The study examined a total of 62 subjects assigned to 2 groups. The herbal compound and Hypozalix were administered for 4 weeks. Efficacy was assessed using the visual analog scale and by grading the degree of dry mouth. Both groups showed a significant difference between visual analog scale before and following intervention. There was also a significant difference in visual analog scale between groups at 4 weeks after onset of intervention. The herbal group showed a significant difference between the grade of dry mouth before and after intervention, but no change was observed for grade of dry mouth in the Hypozalix group. This study supports the efficacy of the herbal compound for controlling symptoms of dry mouth in head and neck cancer patients.

The Epidemic of HPV-Associated Oropharyngeal Cancer Is Here: Is It Time to Change Our Treatment Paradigms?

2011 ◽  
Vol 9 (6) ◽  
pp. 665-673 ◽  
Author(s):  
Erich M. Sturgis ◽  
K. Kian Ang
Keyword(s):  
Clinical Trial ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Oropharyngeal Cancer ◽  
Head And Neck Cancers ◽  
Population Changes ◽  
Clinical Behavior ◽  
Incidence Trends

Although relatively uncommon, oropharyngeal cancers are increasing in incidence despite declining prevalence of smoking and in direct opposition to a decreasing incidence of all other head and neck cancers. An epidemic of human papillomavirus (HPV)–associated oropharyngeal cancers seems to account for these incidence trends. Important demographic, behavioral, and prognostic characteristics define this unique population. Changes in prevention, diagnosis, evaluation, staging, and treatment are needed. This article summarizes the epidemiology and clinical behavior of HPV-associated oropharyngeal cancer and discusses evolving/potential paradigms of treatment. However, data are currently insufficient to change treatment paradigms for HPV-associated oropharyngeal cancer outside of a closely monitored clinical trial.

Sign in / Sign up

Export Citation Format

Share Document